This preposition is somewhat supported by the observed relatively greater decrease in NAA in nur7 mice treated with AAV/Olig001-ASPA, despite being 3-fold less efficient than AAV9-ASPA in transducing its recombinant genome (Figure 5), suggesting targeting oligodendrocytes may be the most efficient and tolerable strategy for Canavan disease. This evidence concerns the gene ASPA and Canavan disease.